A mathematical analysis of adaptations to the metabolic fate of fructose in essential fructosuria subjects

Abstract

Fructose is a major component of Western diets and is implicated in the pathogenesis of obesity and type 2 diabetes. In response to an oral challenge, the majority of fructose is cleared during "first-pass" liver metabolism, primarily via phosphorylation by ketohexokinase (KHK). A rare benign genetic deficiency in KHK, called essential fructosuria (EF), leads to altered fructose metabolism. The only reported symptom of EF is the appearance of fructose in the urine following either oral or intravenous fructose administration. Here we develop and use a mathematical model to investigate the adaptations to altered fructose metabolism in people with EF. First, the model is calibrated to fit available data in normal healthy subjects. Then, to mathematically represent EF subjects, we systematically implement metabolic adaptations such that model simulations match available data for this phenotype. We hypothesize that these modifications represent the major metabolic adaptations present in these subjects. This modeling approach suggests that several other aspects of fructose metabolism, beyond hepatic KHK deficiency, are altered and contribute to the etiology of this benign condition. Specifically, we predict that fructose absorption into the portal vein is altered, peripheral metabolism is slowed, renal reabsorption of fructose is mostly ablated, and alternate pathways for hepatic metabolism of fructose are upregulated. Moreover, these findings have implications for drug discovery and development, suggesting that the therapeutic targeting of fructose metabolism could lead to unexpected metabolic adaptations, potentially due to a physiological response to high-fructose conditions.

A Quantitative Systems Pharmacology Perspective on the Importance of Parameter Identifiability

“…The result is that many large complex models reuse existing models that are not constrained to the specific setting (Fink et al 2011 ; Niederer et al 2009 ), implicitly assuming that inter-species differences, temperature dependence, cell type and experimental protocol have a limited impact on the model prediction of interest. While these assumptions do pose significant limitations on making quantitative predictions, the complex models do provide a physiologically motivated and physically constrained framework for making qualitative estimates of the effect of a novel compound on a physiological system and have a role to play in quantitative systems pharmacology (e.g., Guyton and Coleman 1969 ; Peterson and Riggs 2010 ; Allen et al 2016 ; Allen and Musante 2018 ).…”

A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease

“…QSP models have previously been applied to many physiological systems including COVID-19 ( Dai et al, 2021 ). Notably for understanding NAFLD, there are several prior QSP models that successfully simulate aspects of liver metabolism ( Allen and Musante 2018 ; Noorman et al, 2019 ; Holzhutter and Berndt 2021 ; Siler 2022 ).…”

Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis

“…Activation of key transcription factors such as SREBP1c [10] and ChREBP enhances DNL through upregulation of fatty acid synthase and acetyl-CoA carboxylase [11]. The majority of circulating fructose is cleared on first pass through the hepatic circulation [12] by the ketohexokinase (KHK) enzyme. Fructose, like glucose can also be metabolised by J o u r n a l P r e -p r o o f hexokinase, although the affinity for fructose is much less [13], meaning activity of KHK predominates.…”